Prospective Validation of 18F-FDG Brain PET Discriminant Analysis Methods in the Diagnosis of Amyotrophic Lateral Sclerosis
- PMID: 26940764
- DOI: 10.2967/jnumed.115.166272
Prospective Validation of 18F-FDG Brain PET Discriminant Analysis Methods in the Diagnosis of Amyotrophic Lateral Sclerosis
Abstract
An objective biomarker for early identification and accurate differential diagnosis of amyotrophic lateral sclerosis (ALS) is lacking. (18)F-FDG PET brain imaging with advanced statistical analysis may provide a tool to facilitate this. The objective of this work was to validate volume-of-interest (VOI) and voxel-based (using a support vector machine [SVM] approach) (18)F-FDG PET analysis methods to differentiate ALS from controls in an independent prospective large cohort, using a priori-derived classifiers. Furthermore, the prognostic value of (18)F-FDG PET was evaluated.
Methods: A prospective cohort of patients with a suspected diagnosis of a motor neuron disorder (n = 119; mean age ± SD, 61 ± 12 y; 81 men and 38 women) was recruited. One hundred five patients were diagnosed with ALS (mean age ± SD, 61.0 ± 12 y; 74 men and 31 women) (group 2), 10 patients with primary lateral sclerosis (mean age ± SD, 55.5 ± 12 y; 3 men and 7 women), and 4 patients with progressive muscular atrophy (mean age ± SD, 59.2 ± 5 y; 4 men). The mean disease duration of all patients was 15.0 ± 13.4 mo at diagnosis, with PET conducted 15.2 ± 13.3 mo after the first symptoms. Data were compared with a previously gathered dataset of 20 screened healthy subjects (mean age ± SD, 62.4 ± 6.4 y; 12 men and 8 women) and 70 ALS patients (mean age ± SD, 62.2 ± 12.5 y; 44 men and 26 women) (group 1). Data were spatially normalized and analyzed on a VOI basis (statistical software (using the Hammers atlas) and voxel basis using statistical parametric mapping. Discriminant analysis and SVM were used to classify new cases based on the classifiers derived from group 1.
Results: Compared with controls, ALS patients showed a nearly identical pattern of hypo- and hypermetabolism in groups 1 and 2. VOI-based discriminant analysis resulted in an 88.8% accuracy in predicting the new ALS cases. For the SVM approach, this accuracy was 100%. Brain metabolism between ALS and primary lateral sclerosis patients was nearly identical and not separable on an individual basis. Extensive frontotemporal hypometabolism was predictive for a lower survival using a Kaplan-Meier survival analysis (P < 0.001).
Conclusion: On the basis of a previously acquired training set, (18)F-FDG PET with advanced discriminant analysis methods is able to accurately distinguish ALS from controls and aids in assessing individual prognosis. Further validation on multicenter datasets and ALS-mimicking disorders is needed to fully assess the general applicability of this approach.
Keywords: ALS; PET; discriminant analysis; prognosis; support vector machine.
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Similar articles
-
Multicenter validation of [18F]-FDG PET and support-vector machine discriminant analysis in automatically classifying patients with amyotrophic lateral sclerosis versus controls.Amyotroph Lateral Scler Frontotemporal Degener. 2018 Nov;19(7-8):570-577. doi: 10.1080/21678421.2018.1476548. Epub 2018 Jun 4. Amyotroph Lateral Scler Frontotemporal Degener. 2018. PMID: 29862846
-
Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study.JAMA Neurol. 2014 May;71(5):553-61. doi: 10.1001/jamaneurol.2014.62. JAMA Neurol. 2014. PMID: 24615479
-
Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis.Neurology. 2014 Sep 16;83(12):1067-74. doi: 10.1212/WNL.0000000000000792. Epub 2014 Aug 13. Neurology. 2014. PMID: 25122207
-
Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease.Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1546-1556. doi: 10.1007/s00259-018-4033-0. Epub 2018 May 1. Eur J Nucl Med Mol Imaging. 2018. PMID: 29717332 Review.
-
Positron emission tomography neuroimaging in amyotrophic lateral sclerosis: what is new?Q J Nucl Med Mol Imaging. 2014 Dec;58(4):344-54. Epub 2014 Nov 6. Q J Nucl Med Mol Imaging. 2014. PMID: 25375229 Review.
Cited by
-
Potential of neuroimaging as a biomarker in amyotrophic lateral sclerosis: from structure to metabolism.J Neurol. 2024 Feb 17. doi: 10.1007/s00415-024-12201-x. Online ahead of print. J Neurol. 2024. PMID: 38367047 Review.
-
Primary Lateral Sclerosis: An Overview.J Clin Med. 2024 Jan 19;13(2):578. doi: 10.3390/jcm13020578. J Clin Med. 2024. PMID: 38276084 Free PMC article. Review.
-
PET and SPECT Imaging of ALS: An Educational Review.Mol Imaging. 2023 Aug 19;2023:5864391. doi: 10.1155/2023/5864391. eCollection 2023. Mol Imaging. 2023. PMID: 37636591 Free PMC article. Review.
-
Brainstem-cortex disconnection in amyotrophic lateral sclerosis: bulbar impairment, genotype associations, asymptomatic changes and biomarker opportunities.J Neurol. 2023 Jul;270(7):3511-3526. doi: 10.1007/s00415-023-11682-6. Epub 2023 Apr 6. J Neurol. 2023. PMID: 37022479 Free PMC article.
-
Differences in Cerebral Glucose Metabolism in ALS Patients with and without C9orf72 and SOD1 Mutations.Cells. 2023 Mar 18;12(6):933. doi: 10.3390/cells12060933. Cells. 2023. PMID: 36980274 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous